Federated Hermes Inc. Has $905,000 Stake in Tarsus Pharmaceuticals, Inc. $TARS

Federated Hermes Inc. lowered its holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 72.3% during the third quarter, Holdings Channel.com reports. The firm owned 15,232 shares of the company’s stock after selling 39,789 shares during the period. Federated Hermes Inc.’s holdings in Tarsus Pharmaceuticals were worth $905,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Tarsus Pharmaceuticals by 26.4% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,623 shares of the company’s stock valued at $66,000 after buying an additional 339 shares in the last quarter. Osaic Holdings Inc. lifted its position in Tarsus Pharmaceuticals by 779.1% during the 2nd quarter. Osaic Holdings Inc. now owns 2,778 shares of the company’s stock worth $113,000 after buying an additional 2,462 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in Tarsus Pharmaceuticals by 220.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,045 shares of the company’s stock worth $164,000 after acquiring an additional 2,782 shares during the last quarter. West Wealth Group LLC acquired a new stake in Tarsus Pharmaceuticals in the 3rd quarter valued at about $202,000. Finally, Valeo Financial Advisors LLC acquired a new stake in Tarsus Pharmaceuticals in the 3rd quarter valued at about $209,000. Institutional investors own 90.01% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on TARS shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research report on Thursday, January 22nd. Mizuho initiated coverage on shares of Tarsus Pharmaceuticals in a research report on Thursday, November 20th. They issued an “outperform” rating and a $100.00 price objective for the company. HC Wainwright upped their price objective on Tarsus Pharmaceuticals from $72.00 to $88.00 and gave the stock a “neutral” rating in a report on Monday, October 20th. The Goldman Sachs Group reissued a “neutral” rating and issued a $68.00 target price on shares of Tarsus Pharmaceuticals in a research note on Thursday. Finally, Wall Street Zen upgraded Tarsus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $82.29.

Insider Transactions at Tarsus Pharmaceuticals

In related news, insider Dianne C. Whitfield sold 7,397 shares of the stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $80.10, for a total value of $592,499.70. Following the sale, the insider directly owned 38,958 shares in the company, valued at $3,120,535.80. This trade represents a 15.96% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Bobak R. Azamian sold 6,000 shares of Tarsus Pharmaceuticals stock in a transaction that occurred on Wednesday, December 24th. The stock was sold at an average price of $82.51, for a total transaction of $495,060.00. Following the transaction, the chief executive officer directly owned 857,991 shares in the company, valued at $70,792,837.41. The trade was a 0.69% decrease in their position. The disclosure for this sale is available in the SEC filing. 8.97% of the stock is currently owned by company insiders.

Tarsus Pharmaceuticals Stock Performance

Shares of Tarsus Pharmaceuticals stock opened at $64.62 on Friday. The firm has a fifty day moving average of $75.96 and a two-hundred day moving average of $66.06. The company has a debt-to-equity ratio of 0.22, a quick ratio of 4.25 and a current ratio of 4.29. The stock has a market capitalization of $2.74 billion, a price-to-earnings ratio of -31.99, a PEG ratio of 0.90 and a beta of 0.57. Tarsus Pharmaceuticals, Inc. has a 52 week low of $38.51 and a 52 week high of $85.25.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.05. The business had revenue of $118.70 million during the quarter, compared to analysts’ expectations of $114.22 million. Tarsus Pharmaceuticals had a negative return on equity of 26.29% and a negative net margin of 22.17%. As a group, equities research analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.